IL158140A0 - Multiepitope polypeptides for cancer immunotherapy - Google Patents

Multiepitope polypeptides for cancer immunotherapy

Info

Publication number
IL158140A0
IL158140A0 IL15814003A IL15814003A IL158140A0 IL 158140 A0 IL158140 A0 IL 158140A0 IL 15814003 A IL15814003 A IL 15814003A IL 15814003 A IL15814003 A IL 15814003A IL 158140 A0 IL158140 A0 IL 158140A0
Authority
IL
Israel
Prior art keywords
cancer immunotherapy
multiepitope polypeptides
multiepitope
polypeptides
immunotherapy
Prior art date
Application number
IL15814003A
Other languages
English (en)
Original Assignee
Hadasit Med Res Service
Yissum Res Dev Co
Gavish Galilee Bio Appl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Med Res Service, Yissum Res Dev Co, Gavish Galilee Bio Appl Ltd filed Critical Hadasit Med Res Service
Priority to IL15814003A priority Critical patent/IL158140A0/xx
Publication of IL158140A0 publication Critical patent/IL158140A0/xx
Priority to PCT/IL2004/000894 priority patent/WO2005028505A2/fr
Priority to EP04770565A priority patent/EP1678203A2/fr
Priority to US11/388,794 priority patent/US20060246095A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464492—Glycoprotein 100 [Gp100]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL15814003A 2003-09-25 2003-09-25 Multiepitope polypeptides for cancer immunotherapy IL158140A0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
IL15814003A IL158140A0 (en) 2003-09-25 2003-09-25 Multiepitope polypeptides for cancer immunotherapy
PCT/IL2004/000894 WO2005028505A2 (fr) 2003-09-25 2004-09-26 Polypeptides a epitopes multiples pour l'immunotherapie anticancereuse
EP04770565A EP1678203A2 (fr) 2003-09-25 2004-09-26 Polypeptides a epitopes multiples pour l'immunotherapie anticancereuse
US11/388,794 US20060246095A1 (en) 2003-09-25 2006-03-24 Multiepitope polypeptides for cancer immunotherapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL15814003A IL158140A0 (en) 2003-09-25 2003-09-25 Multiepitope polypeptides for cancer immunotherapy

Publications (1)

Publication Number Publication Date
IL158140A0 true IL158140A0 (en) 2004-03-28

Family

ID=32697196

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15814003A IL158140A0 (en) 2003-09-25 2003-09-25 Multiepitope polypeptides for cancer immunotherapy

Country Status (4)

Country Link
US (1) US20060246095A1 (fr)
EP (1) EP1678203A2 (fr)
IL (1) IL158140A0 (fr)
WO (1) WO2005028505A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034334A2 (fr) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Analogue peptidique capable d'ameliorer la stimulation d'une reponse ctl specifique des gliomes
DE102005041616B4 (de) * 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
GB0524408D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
US20080171062A1 (en) * 2006-08-16 2008-07-17 Monica Sala-Schaeffer Recombinant HBsAg virus-like particles containing polyepitopes of interest, their production and use
CA2700436C (fr) 2006-09-28 2017-04-18 John S. Yu Vaccins contre le cancer et methodes de vaccination
DE102006060824B4 (de) 2006-12-21 2011-06-01 Johannes-Gutenberg-Universität Mainz Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten
US8044363B2 (en) 2007-04-30 2011-10-25 Kimberly-Clark Worldwide, Inc. UV detection devices and methods
DK2470644T3 (en) * 2009-08-24 2017-01-16 Baylor College Medicine GENERATION OF CTL LINES WITH SPECIFICITY AGAINST MORE TUMOR ANTIGEN OR MORE
EP2404618A1 (fr) 2010-07-07 2012-01-11 Stichting Katholieke Universiteit meer in het bijzonder Radboud Universiteit Nijmegen Configuration de protéine immunomodulatoire avec un polymer à squelette hélicale
ES2930809T3 (es) * 2010-08-24 2022-12-22 Univ Pittsburgh Commonwealth Sys Higher Education Vacunas contra el cáncer cerebral basadas en el péptido receptor de interleucina-13 alfa 2
SI2714071T1 (sl) 2011-05-24 2019-11-29 Biontech Rna Pharmaceuticals Gmbh Individualizirana cepiva proti raku
AU2012261237B2 (en) 2011-05-24 2017-06-01 BioNTech SE Individualized vaccines for cancer
IN2014MN00433A (fr) * 2011-09-07 2015-06-19 Midatech Ltd
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
HRP20221303T1 (hr) 2012-02-09 2022-12-23 Baylor College Of Medicine SMJESE PEPTIDA ZA NASTAJANJE MULTIVIRUSNIH CITOTOKSIČNIH T-LIMFOCITA(CTLs) ŠIROKE SPECIFIČNOSTI
WO2014127296A1 (fr) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Vaccins contre le cancer et méthodes de vaccination
WO2017049291A1 (fr) 2015-09-18 2017-03-23 Baylor College Of Medicine Identification d'antigène immunogène à partir d'un pathogène et corrélation avec l'efficacité clinique
CN106854649B (zh) * 2016-12-16 2019-05-21 中国人民解放军南京军区福州总医院 金黄色葡萄球菌肠毒素c2的核酸适配体c204及其筛选方法和应用
US10821134B2 (en) 2017-05-17 2020-11-03 Board Of Regents, The University Of Texas System BK virus specific T cells
US11028139B2 (en) * 2017-05-17 2021-06-08 Nexel Co., Ltd. Recombinant protein for preventing or treating tissue fibrosis and composition for preventing or treating tissue fibrosis comprising the same
US10772914B1 (en) 2019-04-18 2020-09-15 Baylor College Of Medicine EBV-specific immune cells
US20230002446A1 (en) * 2019-06-06 2023-01-05 The University Of Sydney Anti-inflammatory agents
CN114591401A (zh) * 2021-05-18 2022-06-07 深圳市因诺转化医学研究院 SARS-CoV-2编码蛋白来源的T细胞表位多肽HLVDFQVTI及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396116B1 (fr) * 1989-05-02 1997-02-05 Abbott Laboratories Fixation covalente des membres de liaison spécifiques aux phases solides
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
EP0919243A1 (fr) * 1997-11-25 1999-06-02 Duphar International Research B.V Vaccin dont l'adjuvant est constitué de sous-unités B de l'entérotoxine thermolabile (LTB) d'Escherichia coli
JP2002507393A (ja) * 1998-02-11 2002-03-12 マキシジェン， インコーポレイテッド 抗原ライブラリー免疫
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines

Also Published As

Publication number Publication date
US20060246095A1 (en) 2006-11-02
EP1678203A2 (fr) 2006-07-12
WO2005028505A2 (fr) 2005-03-31
WO2005028505A3 (fr) 2005-10-20

Similar Documents

Publication Publication Date Title
IL158140A0 (en) Multiepitope polypeptides for cancer immunotherapy
IL174510A0 (en) Tim-3 polypeptides
GB0324368D0 (en) Polypeptides including modified constant regions
EP1616881A4 (fr) Anticorps anti-mpl
IL175608A0 (en) Antibodies
GB0228900D0 (en) Cancer Immunotherapy
EP1496923A4 (fr) Immunotherapie du cancer
AU2003264488A1 (en) Immunotherapeutic for cancer
GB0223696D0 (en) Improved immunotherapy
GB0401876D0 (en) New use for cancer antigen
GB0220658D0 (en) Immunotherapy
IL174361A0 (en) Clq RELATED PROTEIN
EP1596813A4 (fr) Polypeptides exprimes par les poumons
EP1614695A4 (fr) Polypeptide
EP1693069A4 (fr) Remede permettant de traiter une tumeur solide
EP1595546A4 (fr) Remede contre le cancer
GB0306428D0 (en) Receptor proteins
GB2397873B (en) Reflector apparatus
GB0328690D0 (en) Tumour suppressor protein
GB0311108D0 (en) Proteins
IL155972A0 (en) Cardiotonic polypeptides
GB0329173D0 (en) Polypeptides
GB0302177D0 (en) Polypeptides
GB0303133D0 (en) Polypeptide
GB0306261D0 (en) Polypeptide